Daniel R. Carrizosa
Expertise in
15
conditions

Dr. Daniel R. Carrizosa

Hematology | Oncology
1021 Morehead Medical Drive, Building 2, Suite 30500, 
Charlotte, NC 
On Staff At
Accepting New Patients
Offers Telehealth
Expertise in
15
conditions
1021 Morehead Medical Drive, Building 2, Suite 30500, 
Charlotte, NC 

Overview

Daniel Carrizosa is a Hematologist and an Oncologist in Charlotte, North Carolina. Dr. Carrizosa is highly rated in 15 conditions, according to our data. His top areas of expertise are Lung Cancer, Nasopharyngeal Carcinoma, Pleuropulmonary Blastoma, and Non-Small Cell Lung Cancer (NSCLC). Dr. Carrizosa is currently accepting new patients.

His clinical research consists of co-authoring 28 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Institution

The University Of North Carolina

Residency

The University of North Carolina, Internal Medicine

Specialties

Hematology
Oncology

Licenses

Internal Medicine in NC

Board Certifications

American Board Of Internal Medicine, Medical Oncology

Fellowships

The University of North Carolina, Hematology/Oncology

Hospital Affiliations

Atrium Health Union
Carolinas Medical Center/behav Health

Languages Spoken

English
Spanish

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Oscar
  • EPO
  • HMO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 7 Less Insurance Carriers -

Locations

Atrium Health Levine Cancer Institute (Thoracic-Pulmonary)
1021 Morehead Medical Drive, Building 2, Suite 30500, Charlotte, NC 28204

Additional Areas of Focus

Dr. Carrizosa has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Lung Cancer
Prostate Cancer
B-Cell Lymphoma
Interstitial Lung Disease
Colorectal Cancer
Leukemia
Multiple Myeloma
Adult T-Cell Leukemia
Liver Cancer

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

Phase II Randomized Study of Maintenance Atezolizumab Versus Atezolizumab in Combination With Talazoparib in Patients With SLFN11 Positive Extensive Stage Small Cell Lung Cancer (ES-SCLC)
Phase II Randomized Study of Maintenance Atezolizumab Versus Atezolizumab in Combination With Talazoparib in Patients With SLFN11 Positive Extensive Stage Small Cell Lung Cancer (ES-SCLC)
Enrollment Status: Active_not_recruiting
Publish Date: February 12, 2026
Intervention Type: Procedure, Drug
Study Drugs: Atezolizumab, Talazoparib
Study Phase: Phase 2
Randomized Phase II/III Trial of Radiotherapy With Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy With Concurrent Cetuximab in Patients With Locoregionally Advanced Head and Neck Cancer With a Contraindication to Cisplatin
Randomized Phase II/III Trial of Radiotherapy With Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy With Concurrent Cetuximab in Patients With Locoregionally Advanced Head and Neck Cancer With a Contraindication to Cisplatin
Enrollment Status: Completed
Publish Date: February 06, 2026
Intervention Type: Other, Biological, Radiation
Study Drugs: Cetuximab, Durvalumab
Study Phase: Phase 2/Phase 3
Limited Stage Small Cell Lung Cancer (LS-SCLC): A Phase III Randomized Study of Chemoradiation Versus Chemoradiation Plus Atezolizumab
Limited Stage Small Cell Lung Cancer (LS-SCLC): A Phase III Randomized Study of Chemoradiation Versus Chemoradiation Plus Atezolizumab
Enrollment Status: Active_not_recruiting
Publish Date: December 03, 2025
Intervention Type: Other, Drug, Radiation, Procedure
Study Drugs: Atezolizumab, Carboplatin, Cisplatin, Etoposide
Study Phase: Phase 3
Maintenance Systemic Therapy Versus Local Consolidative Therapy (LCT) Plus Maintenance Systemic Therapy for Limited Metastatic Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase II/III Trial
Maintenance Systemic Therapy Versus Local Consolidative Therapy (LCT) Plus Maintenance Systemic Therapy for Limited Metastatic Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase II/III Trial
Enrollment Status: Active_not_recruiting
Publish Date: November 25, 2025
Intervention Type: Radiation, Drug
Study Drugs: Docetaxel, Gemcitabine, Pemetrexed Disodium, Erlotinib Hydrochloride, Pembrolizumab
Study Phase: Phase 2
EA5163/S1709 INSIGNA : A Randomized, Phase III Study of Firstline Immunotherapy Alone or in Combination With Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) With Immunobiomarker SIGNature-Driven Analysis
EA5163/S1709 INSIGNA : A Randomized, Phase III Study of Firstline Immunotherapy Alone or in Combination With Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) With Immunobiomarker SIGNature-Driven Analysis
Enrollment Status: Active_not_recruiting
Publish Date: November 25, 2025
Intervention Type: Procedure, Drug, Biological
Study Drugs: Carboplatin, Pembrolizumab, Pemetrexed
Study Phase: Phase 3
A Phase 1/2 Study of the Safety, Pharmacokinetics, and Anti-Tumor Activity of the Oral EGFR/HER2 Inhibitor TAK-788 (AP32788) in Non-Small Cell Lung Cancer
A Phase 1/2 Study of the Safety, Pharmacokinetics, and Anti-Tumor Activity of the Oral EGFR/HER2 Inhibitor TAK-788 (AP32788) in Non-Small Cell Lung Cancer
Enrollment Status: Active_not_recruiting
Publish Date: March 06, 2025
Intervention Type: Drug
Study Drugs: TAK-788, Pemetrexed, Carboplatin
Study Phase: Phase 1/Phase 2
A Randomized, Double-blind, Adaptive, Phase II/III Study of GSK3359609 or Placebo in Combination With Pembrolizumab for First-Line Treatment of PD-L1 Positive Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
A Randomized, Double-blind, Adaptive, Phase II/III Study of GSK3359609 or Placebo in Combination With Pembrolizumab for First-Line Treatment of PD-L1 Positive Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Enrollment Status: Terminated
Publish Date: July 10, 2024
Intervention Type: Drug
Study Drugs: Feladilimab, Pembrolizumab
Study Phase: Phase 3
View 6 Less Clinical Trials

28 Total Publications

Olaparib in Patients With Solid Tumors With ATM Alterations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.
Olaparib in Patients With Solid Tumors With ATM Alterations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.
Journal: JCO precision oncology
Published: January 15, 2026
Similar Doctors
Ruben A. Mesa
Expertise in
18
conditions
Dr. Ruben A. Mesa
Hematology | Oncology
Expertise in
18
conditions
Dr. Ruben A. Mesa
Hematology | Oncology

Atrium Health Levine Cancer Institute

1021 Morehead Medical Drive, 
Charlotte, NC 
 (0.1 miles away)
980-442-2000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Ruben Mesa is a Hematologist and an Oncologist in Charlotte, North Carolina. Dr. Mesa is highly rated in 18 conditions, according to our data. His top areas of expertise are Myelofibrosis, Polycythemia Vera, Myeloproliferative Neoplasms (MPN), Bone Marrow Transplant, and Splenectomy. Dr. Mesa is currently accepting new patients.

Manisha Bhutani
Expertise in
11
conditions
Dr. Manisha Bhutani
Hematology | Oncology
Expertise in
11
conditions
Dr. Manisha Bhutani
Hematology | Oncology

Atrium Health Levine Cancer Institute (Hematology)

1021 Morehead Medical Drive, Building 2, Suite 60201, 
Charlotte, NC 
 (0.1 miles away)
980-442-4363
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Manisha Bhutani is a Hematologist and an Oncologist in Charlotte, North Carolina. Dr. Bhutani is highly rated in 11 conditions, according to our data. Her top areas of expertise are Multiple Myeloma, Smoldering Multiple Myeloma, Monoclonal Gammopathy of Undetermined Significance (MGUS), Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Bhutani is currently accepting new patients.

Expertise in
7
conditions
Dr. Ifeyinwa Osunkwo
Hematology | Oncology
Expertise in
7
conditions
Dr. Ifeyinwa Osunkwo
Hematology | Oncology

Office

1021 Morehead Medical Dr, 
Charlotte, NC 
 (0.1 miles away)
980-442-2000
Languages Spoken:
English
See accepted insurances

Ifeyinwa Osunkwo is a Hematologist and an Oncologist in Charlotte, North Carolina. Dr. Osunkwo is highly rated in 7 conditions, according to our data. Her top areas of expertise are Sickle Cell Disease, Congenital Hemolytic Anemia, Hemoglobinopathy, and Hemolytic Anemia.

Frequently Asked Questions about Dr. Daniel R. Carrizosa

How do I make an appointment with Dr. Daniel R. Carrizosa?

You can book an appointment with Dr. Daniel R. Carrizosa by calling their office at 980-442-3300. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Daniel R. Carrizosa a top-rated expert for Lung Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Daniel R. Carrizosa is classified as an Distinguished expert for Lung Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Daniel R. Carrizosa specialize in?

While Dr. Daniel R. Carrizosa is a Hematology, they have specific expertise in Lung Cancer, Nasopharyngeal Carcinoma, and Pleuropulmonary Blastoma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Daniel R. Carrizosa participate in research or clinical trials?

Yes. Dr. Daniel R. Carrizosa has published 28 articles and abstracts on conditions like Lung Cancer. You can view a list of Dr. Daniel R. Carrizosa's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Daniel R. Carrizosa accept my insurance?

Dr. Daniel R. Carrizosa accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 980-442-3300 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Carrizosa's expertise for a condition
ConditionClose
    View All 12 Advanced Conditions
    View All 55 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile